HUE037382T2 - Eljárás rák kezelésére targeting NQOl alkalmazásával - Google Patents

Eljárás rák kezelésére targeting NQOl alkalmazásával

Info

Publication number
HUE037382T2
HUE037382T2 HUE11827555A HUE11827555A HUE037382T2 HU E037382 T2 HUE037382 T2 HU E037382T2 HU E11827555 A HUE11827555 A HU E11827555A HU E11827555 A HUE11827555 A HU E11827555A HU E037382 T2 HUE037382 T2 HU E037382T2
Authority
HU
Hungary
Prior art keywords
nqo1
targeting
methods
treating cancer
cancer
Prior art date
Application number
HUE11827555A
Other languages
English (en)
Inventor
David Boothman
Jinming Gao
Erik Bey
Ying Dong
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HUE037382T2 publication Critical patent/HUE037382T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE11827555A 2010-09-22 2011-09-22 Eljárás rák kezelésére targeting NQOl alkalmazásával HUE037382T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38541110P 2010-09-22 2010-09-22

Publications (1)

Publication Number Publication Date
HUE037382T2 true HUE037382T2 (hu) 2018-08-28

Family

ID=45874170

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11827555A HUE037382T2 (hu) 2010-09-22 2011-09-22 Eljárás rák kezelésére targeting NQOl alkalmazásával

Country Status (10)

Country Link
US (1) US9469878B2 (hu)
EP (1) EP2619331B1 (hu)
DK (1) DK2619331T3 (hu)
ES (1) ES2671248T3 (hu)
HU (1) HUE037382T2 (hu)
NO (1) NO2619331T3 (hu)
PL (1) PL2619331T3 (hu)
PT (1) PT2619331T (hu)
TR (1) TR201807363T4 (hu)
WO (1) WO2012040492A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2678649T3 (es) 2011-10-14 2018-08-14 The Board Of Trustees Of The Universityof Illinois Compuestos y sustratos de nqo1 antitumorales
US10272099B2 (en) * 2013-04-09 2019-04-30 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy
CN103667447A (zh) * 2013-11-04 2014-03-26 武汉艾迪康医学检验所有限公司 用于检测nqo1基因多态性的引物、试剂盒及其在病理检测上的应用
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
JP2022525476A (ja) * 2019-03-18 2022-05-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍選択的併用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60031268T2 (de) 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
CA2466148C (en) * 2001-11-01 2013-01-08 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
RU2396953C2 (ru) * 2006-02-09 2010-08-20 Спектрум Фармасьютикалз, Инк. Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля
WO2008106129A2 (en) 2007-02-26 2008-09-04 Wisconsin Alumni Research Foundation Polymeric micelles for combination drug delivery
ES2626437T3 (es) 2010-09-22 2017-07-25 The Board Of Regents Of The University Of Texas System Copolímero en bloque novedoso y composiciones micelares y procedimientos de uso de las mismas

Also Published As

Publication number Publication date
NO2619331T3 (hu) 2018-07-28
PL2619331T3 (pl) 2018-10-31
US9469878B2 (en) 2016-10-18
WO2012040492A1 (en) 2012-03-29
EP2619331A4 (en) 2014-03-05
ES2671248T3 (es) 2018-06-05
PT2619331T (pt) 2018-06-01
US20130253046A1 (en) 2013-09-26
EP2619331A1 (en) 2013-07-31
DK2619331T3 (en) 2018-06-06
EP2619331B1 (en) 2018-02-28
TR201807363T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL223189A0 (en) Methods of treatment of pancreatic cancer
HK1202253A1 (en) Combination treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
EP2643001A4 (en) METHOD OF TREATING CANCER
HK1189272A1 (zh) 治療癌症的方法
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
IL228430A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
PL2619331T3 (pl) Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1
EP2585115A4 (en) ANTICANCER TREATMENT
WO2012106461A9 (en) Combination therapy for treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
EP2750691A4 (en) SRPX IN THE TREATMENT OF CANCER
ZA201208905B (en) Cancer therapy method
GB201121791D0 (en) Combination treatment of cancer
GB201020513D0 (en) Cancer therapy
GB201121783D0 (en) Treatment of cancer